Report an adverse reaction

Ru Eng

News

01/13/2025

GENERIUM has registered the first domestic device for analyzing tuberculosis test results.

GENERIUM has received a registration certificate for the medical device "SCREENSPOT" - a microplate analyzer for automated reading and analysis of tuberculosis test results based on the ELISPOT method. The equipment is intended for clinical diagnostic laboratories and is capable of enhancing their operational efficiency.

GENERIUM has registered the first domestic device for analyzing tuberculosis test results.

The Ministry of Health of the Russian Federation has registered the first biosimilar of tocilizumab - a drug from the company GENERIUM.

The Ministry of Health of the Russian Federation has registered the first biosimilar of tocilizumab - a drug from the company GENERIUM.

The first biosimilar of tocilizumab, developed by Russian scientists and registered by the Ministry of Health of Russia, has been named Complarate©. The drug helps to suppress systemic inflammatory responses and is intended for the treatment of rheumatoid arthritis, including systemic juvenile idiopathic arthritis, therapy for severe conditions related to COVID-19, and life-threatening cytokine release syndrome.

GENERIUM – the first in Russia to receive a registration certificate for a biomedical cell product

GENERIUM – the first in Russia to receive a registration certificate for a biomedical cell product

The first advanced therapy medicinal product (ATMP) in Russia was registered by GENERIUM under the trade name EASYTENSE. It is an autologous product based on chondrocytes, the main cells of cartilage tissue, and is intended for the restoration of damage to the cartilage of the knee joint with a defect area of up to 10 square cm.

GENERIUM has registered a biosimilar of ranibizumab, a medicine for treatment of age-related macular degeneration

GENERIUM has registered a biosimilar of ranibizumab, a medicine for treatment of age-related macular degeneration

The medicine from GENERIUM under the trade name Laxolan® received a registration certificate from the Ministry of Health. It is intended to treat age-related macular degeneration, as well as certain other retinal diseases that are a common cause of vision loss.

The first biosimilar of romiplostim has been registered in Russia

The first biosimilar of romiplostim has been registered in Russia

The first biosimilar of the orphan drug romiplostim has been registered in Russia, which is used as a treatment for immune thrombocytopenia and is included in the List of Vital and Essential Drugs. The registration certificate for the drug "Stimplate" produced by the company "Generium" was issued by the Ministry of Health of Russia.

Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product

Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product

Third Biosimilar to Reach the Market Under Selexis/Generium Commercial License Agreements

Expo 2020 in Dubai: Russian Pharma Industry Adapts to Pandemic, Open to Cooperation With Arab World

Expo 2020 in Dubai: Russian Pharma Industry Adapts to Pandemic, Open to Cooperation With Arab World

The 13th meeting of the Russian-Arab Business Council session was held on 25-26 January.

Russia shows off new Covid-19 vaccine factory even as its people hesitate to get the shot

Russia shows off new Covid-19 vaccine factory even as its people hesitate to get the shot

Volginsky, Russia (CNN) — Decades ago, Soviet scientists researched biological weapons at a site in Volginsky, about 70 miles east of Moscow. Now, that site is being used to mass-produce a vaccine aimed at protecting people around the world from the coronavirus.

Talks on production of Russian vaccine in Serbia commence

Talks on production of Russian vaccine in Serbia commence

Minister without portfolio in charge of innovations and technological development Nenad Popovic visited today the production capacities of the largest Russian vaccine manufacturer "Sputnik V" - Generium in the Vladimir region in Russia.

GENERIUM launched the production of Sputnik V vaccine

GENERIUM launched the production of Sputnik V vaccine

Moscow, 26 October 2020. The Ministry of Health of the Russian Federation has included a biotechnology company GENERIUM in the marketing authorisation as a manufacturer of Gam-COVID-Vac (Sputnik V) vaccine for the prevention of COVID-19.

Read more: